Last updated: September 22, 2026
Bedaquiline fumarate is the active pharmaceutical ingredient in Johnson & Johnson’s Sirturo, a diarylquinoline used in multidrug-resistant tuberculosis (MDR-TB). Its commercial profile differs from most branded drugs: demand is driven primarily by public-health programs, international procurement and treatment guidelines rather than private prescriptions.
The product entered a post-core-patent phase after the main composition-of-matter protection expired in major markets. Revenue has remained supported by global MDR-TB demand, pediatric formulations, procurement contracts and newer treatment regimens that place bedaquiline at the center of tuberculosis therapy. Generic competition is increasing, particularly in low- and middle-income countries, but regulatory, manufacturing and procurement barriers continue to limit rapid substitution.
What is bedaquiline fumarate and how is Sirturo used?
Bedaquiline fumarate is the fumarate salt of bedaquiline, a selective inhibitor of mycobacterial ATP synthase. Sirturo is approved with other medicines for pulmonary MDR-TB in adults and adolescents. The FDA initially approved the drug in December 2012 under the accelerated approval pathway based on sputum culture conversion data. The indication later expanded to include pediatric patients aged five years and older and weighing at least 15 kilograms, with pediatric granules added to support administration in younger patients.[1]
| Product |
Active ingredient |
Developer |
Primary indication |
Regulatory status |
| Sirturo |
Bedaquiline fumarate |
Janssen, a Johnson & Johnson company |
Pulmonary MDR-TB |
FDA-approved |
| Generic bedaquiline |
Bedaquiline fumarate |
Multiple manufacturers |
MDR-TB treatment |
Approved or supplied in multiple international markets |
| Pretomanid combination |
Pretomanid with bedaquiline and linezolid |
TB Alliance and partners |
Selected cases of highly drug-resistant TB |
Approved in the U.S. as part of the BPaL regimen |
Bedaquiline is also used in combination regimens containing linezolid, clofazimine, fluoroquinolones and other anti-TB medicines. WHO treatment guidance has placed bedaquiline in preferred all-oral regimens for drug-resistant TB, materially increasing its clinical importance.[2]
When does bedaquiline lose exclusivity?
The principal U.S. composition-of-matter patent protection has expired or reached the end of its effective term, depending on the specific patent and jurisdiction. Regulatory exclusivity also expired before the current generic expansion phase.
| Exclusivity category |
Bedaquiline status |
| FDA new chemical entity exclusivity |
Expired after the five-year period beginning with the 2012 approval |
| Orphan-drug exclusivity |
The seven-year period associated with the original orphan indication ended or reached its terminal phase during the 2020s |
| Core composition patents |
Expired or reached terminal patent-term dates in major markets |
| Formulation and pediatric patents |
May extend beyond the core compound term, subject to jurisdiction and claim scope |
| Method-of-use patents |
Can remain relevant where claims cover specific MDR-TB regimens, dosing schedules or patient populations |
| International procurement protection |
Depends on national patent law, voluntary licenses and supplier qualification |
The precise loss-of-exclusivity date is not uniform globally. Patent term adjustment, supplementary protection certificates, pediatric extensions, national validation and claim limitations affect the commercial position in each country.
What patents protect bedaquiline fumarate?
Bedaquiline’s original patent estate covered diarylquinoline compounds and their use against mycobacterial infections. The principal commercial barrier was the composition patent covering the bedaquiline chemical series and related salts.
Public patent records identify Janssen-related protection covering:
| Patent category |
Typical protected subject matter |
Commercial relevance |
| Core compound patents |
Diarylquinoline molecules, including bedaquiline-type structures |
Primary historical barrier to generic entry |
| Salt patents |
Fumarate and other pharmaceutically acceptable salts |
Relevant to the marketed drug substance |
| Formulation patents |
Tablets, dispersible forms, granules and pharmaceutical compositions |
More important for pediatric and differentiated products |
| Method-of-use patents |
Treatment of MDR-TB and administration with companion drugs |
Potential basis for a narrower infringement dispute |
| Manufacturing patents |
Processes for producing intermediates, salts or final drug substance |
Can increase supplier qualification and scale-up costs |
The original composition protection carried the greatest value because a generic product using the same active moiety would generally need to address that patent. After expiration, remaining formulation or method claims have less ability to block a conventional adult tablet if the generic does not practice the narrower claimed features.
What is the Orange Book status of Sirturo?
Sirturo’s Orange Book position is more important for U.S. generic timing than the existence of a global patent portfolio. An ANDA applicant must certify against listed patents, generally through Paragraph I, II, III or IV certification.
The principal U.S. issues are:
- Whether any unexpired Sirturo patent remains listed for the proposed dosage form.
- Whether the generic applicant seeks approval for the same indication or uses a section viii statement to omit patented uses.
- Whether the applicant challenges a listed patent through a Paragraph IV certification.
- Whether a patent dispute triggers the 30-month stay under the Hatch-Waxman Act.
- Whether pediatric exclusivity or other regulatory extensions affect approval timing.
Publicly visible litigation and patent records do not indicate a major, widely reported U.S. Paragraph IV campaign comparable with the litigation histories of high-revenue oncology, immunology or diabetes products. The lack of a large U.S. litigation record does not eliminate generic risk. It indicates that the principal commercial contest is more likely to occur through ANDA timing, procurement pricing and international supply agreements than through high-value patent settlements.
How strong is the bedaquiline patent estate?
The estate is strongest against an unlicensed copy during the life of the core composition patent and weaker after that patent’s expiration.
| Patent-strength factor |
Assessment |
| Core chemical protection |
Historically strong, but largely exhausted in major markets |
| Salt protection |
Moderate, depending on claim drafting and validity |
| Adult tablet protection |
Limited after core patent expiry unless a live formulation patent covers the product |
| Pediatric granule protection |
Stronger where the generic does not have an equivalent dosage form |
| Method-of-use protection |
Potentially relevant, but can be avoided through labeling strategies |
| Manufacturing protection |
Can delay or raise costs but rarely blocks all alternative production routes |
| International enforceability |
Highly variable across countries |
| Procurement leverage |
Stronger than residual patent leverage in many low-income markets |
The remaining estate is therefore better described as a segmented protection structure than as a single blocking patent. Product differentiation may remain defensible in pediatric delivery systems, fixed-dose combinations, improved tolerability, and manufacturing processes.
Which companies are challenging or supplying bedaquiline?
Generic and alternative supply has expanded through international procurement channels. Manufacturers associated with bedaquiline supply include Indian pharmaceutical companies and other suppliers qualified by national regulators or global procurement organizations. The commercial field has included companies such as Macleods Pharmaceuticals, Lupin, Viatris-related entities and other suppliers, depending on country and procurement status.
The most important access development was Johnson & Johnson’s agreement with the Medicines Patent Pool and related public-health procurement mechanisms. The arrangement enabled qualified manufacturers to supply generic bedaquiline in selected low- and middle-income countries, with the Global Drug Facility acting as a major procurement channel.[3][4]
This structure reduces patent friction in covered territories while preserving a commercial market for Janssen in countries outside the license scope and in segments where branded supply, regulatory status or procurement preference remains important.
What formulation patents protect Sirturo?
The marketed product has historically been supplied as 100 mg tablets. Pediatric treatment requires dosage forms that can be swallowed or administered more easily than conventional tablets. Janssen’s pediatric development included granules for oral suspension, creating a potential differentiation point after adult tablet patent expiry.
Adult tablets
Adult tablets are the most exposed to generic competition. Once the main compound barrier is unavailable, a supplier with an approved bioequivalent product can compete primarily on price, availability and procurement qualification.
Pediatric granules
Pediatric granules have greater product-specific protection because the dosage form requires separate development, stability data, manufacturing controls and regulatory approval. Generic manufacturers may need to conduct additional formulation and bioequivalence work rather than simply reproduce the adult tablet.
Fixed-dose combinations
Bedaquiline is increasingly used within combination regimens, although the clinical and regulatory status of fixed-dose products differs by country. Combination products can create new patent and regulatory questions involving formulation compatibility, release profiles, stability and dosing.
How does bedaquiline compare with delamanid and pretomanid?
Bedaquiline has a stronger market position than delamanid because WHO treatment guidance has made it a central component of preferred MDR-TB regimens. Pretomanid has strategic importance in the BPaL regimen but is used in a narrower treatment context.
| Factor |
Bedaquiline |
Delamanid |
Pretomanid |
| Drug class |
Diarylquinoline |
Nitro-dihydro-imidazooxazole |
Nitroimidazole |
| Main commercial role |
Backbone of many MDR-TB regimens |
Alternative or companion drug |
Component of selected BPaL regimens |
| Global procurement depth |
High |
Lower |
More specialized |
| Generic competition |
Increasing |
Increasing |
More limited in some markets |
| Patent risk |
Core protection largely exhausted |
Country-specific |
Combination and use rights remain relevant |
| Revenue model |
Public-health procurement |
Public-health procurement |
Combination-regimen and access-based |
Bedaquiline’s competitive advantage is clinical positioning and procurement scale rather than continuing exclusivity over the active ingredient.
What is the FDA regulatory status of bedaquiline?
The FDA approved Sirturo in 2012 under accelerated approval. The approval required postmarketing studies to verify clinical benefit. The FDA later approved pediatric use and a granule formulation for children. Bedaquiline is also part of the FDA-approved BPaL regimen for certain forms of highly drug-resistant pulmonary TB, in combination with pretomanid and linezolid.[1][5]
The regulatory pathway creates continuing obligations around safety, cardiac monitoring and drug interactions. QT prolongation is a known concern, particularly when bedaquiline is combined with other medicines that affect cardiac repolarization. These safety requirements add clinical-management complexity but do not generally prevent generic substitution when the generic product has the same active ingredient, strength and approved labeling.
What patent litigation and settlement agreements affect bedaquiline?
The bedaquiline market has not produced a major public U.S. patent-litigation profile. Its most consequential legal and commercial development has been voluntary licensing rather than a large-scale originator-generic settlement.
The key arrangement is the license enabling generic production and supply in specified low- and middle-income countries through the Medicines Patent Pool and related procurement channels. The practical effect is:
- reduced litigation risk in covered countries;
- broader supplier participation;
- lower procurement prices;
- greater reliance on international quality-assurance systems;
- continuing geographic segmentation of the market.
A license does not eliminate all patent or regulatory barriers. It applies only to defined territories, suppliers and conditions. Countries outside the license may retain different patent positions, regulatory requirements and procurement rules.
What generic entry risks exist for Sirturo?
Generic entry risk is high in markets with expired compound patents and established public procurement systems. The risk is lower where national registration is slow, demand is small, local manufacturing is weak or pediatric formulations are not available.
High-risk markets
Generic pressure is strongest in:
- countries covered by voluntary licensing;
- markets that rely on Global Drug Facility procurement;
- countries with expired bedaquiline patents;
- public programs that select suppliers through competitive tender;
- markets where adult tablets account for most demand.
Moderate-risk markets
Risk is moderate where:
- patents have expired but regulatory approval is limited;
- a small number of qualified suppliers exist;
- procurement agencies prioritize supply continuity;
- pediatric formulations remain less competitive.
Lower-risk segments
The most defensible segments are:
- branded pediatric granules;
- markets with live formulation claims;
- territories without license coverage;
- government programs requiring a specific quality-assured supplier;
- differentiated combination products.
Generic launches are more likely to reduce price and volume than to eliminate branded supply immediately. Tuberculosis programs often maintain dual sourcing to prevent shortages and manage resistance risk.
What is the revenue trajectory for bedaquiline fumarate?
Bedaquiline revenue has a distinctive financial pattern. It is a commercially meaningful product for Janssen but not a mass-market blockbuster. Revenue is constrained by low-income-country pricing, public procurement budgets and the limited size of the MDR-TB patient population. Demand is supported by guideline adoption and treatment expansion.
| Revenue driver |
Directional impact |
| WHO preference for bedaquiline-based regimens |
Positive |
| Expansion of MDR-TB diagnosis |
Positive |
| Generic licensing |
Negative for price and branded share |
| Public procurement concentration |
Negative for margins |
| Pediatric formulation expansion |
Positive but limited in scale |
| New all-oral treatment regimens |
Positive for utilization |
| Drug-resistance prevention and treatment access |
Positive for volume |
| Core patent expiry |
Negative for long-term pricing |
Janssen’s financial exposure is therefore shifting from monopoly pricing toward volume, access agreements and lifecycle management. The commercial value of the franchise remains tied to the company’s ability to preserve supply contracts, support treatment guidelines and retain differentiated formulations.
The broader market opportunity is larger than branded revenue suggests. Bedaquiline is a platform component in global MDR-TB treatment, and its demand can rise even as the originator’s price and market share fall.
How do licensing deals affect the bedaquiline market?
Licensing has converted bedaquiline from a conventional branded product into a split market:
- Originator and licensed supply in covered low- and middle-income countries.
- Generic and local supply in countries with expired or absent patent barriers.
- Branded or originator-controlled supply in markets with stronger commercial pricing.
- Procurement-led competition through public-health agencies.
The Medicines Patent Pool arrangement is strategically important because it accelerates supplier entry without requiring each manufacturer to negotiate separately with the originator. It also aligns production with WHO prequalification and Global Drug Facility procurement requirements.[3][4]
For investors and licensors, the agreement reduces litigation upside but increases the probability of predictable, lower-margin volume. For manufacturers, the principal opportunity is not premium pricing. It is qualification, reliable supply and access to tenders.
What is the outlook for bedaquiline generic launches?
The most likely launch pattern is staggered rather than simultaneous.
Near term
More suppliers enter public-health markets where licensing and patent conditions are favorable. Prices decline, but demand remains stable or rises as countries adopt shorter all-oral regimens.
Medium term
Adult tablet competition becomes routine. Originator revenue becomes increasingly dependent on pediatric products, markets outside the license, supply agreements and regulatory positioning.
Longer term
Bedaquiline becomes a procurement commodity in many countries. Competitive advantage shifts to manufacturing cost, quality assurance, delivery reliability and inclusion in national treatment programs.
The largest barriers to entry are likely to be regulatory approval, quality-assurance qualification, manufacturing scale, stable active pharmaceutical ingredient supply and access to public tenders. Residual patents matter, but they are only one part of the entry equation.
What is the geographic coverage of bedaquiline protection?
Bedaquiline’s geographic position is fragmented. Patent terms vary by country, while voluntary licenses cover defined territories. The commercial assessment should be performed country by country rather than through a single global expiration date.
| Geographic segment |
Commercial condition |
| United States |
Mature regulatory market; ANDA and Orange Book analysis required |
| European markets |
Core protection largely exhausted; national and regional patent status must be checked |
| India |
Major manufacturing base and strong generic supply potential |
| Sub-Saharan Africa |
Public procurement and license coverage are major drivers |
| Southeast Asia |
Patent status, local registration and tender rules vary |
| Latin America |
Country-specific registration and procurement conditions |
| Least-developed countries |
Access agreements and donor procurement often outweigh patent barriers |
Key Takeaways
- Bedaquiline fumarate is the active ingredient in Sirturo and a core medicine for MDR-TB.
- The original composition-of-matter exclusivity has largely run its course in major markets.
- Residual formulation, pediatric and method-of-use patents may still matter, but they have narrower blocking power.
- Public procurement, WHO guidance and licensing agreements are more important than private retail demand.
- Generic competition is strongest in licensed low- and middle-income markets.
- Janssen’s revenue trajectory is likely to reflect lower prices, broader volume and reduced exclusivity.
- Pediatric granules, supply contracts and regulatory status are the principal remaining commercial differentiators.
- No major public U.S. Paragraph IV litigation campaign defines the current market.
- The highest entry barriers are quality assurance, procurement qualification, manufacturing scale and reliable supply.
- Geographic patent analysis is essential because patent expiry and license coverage are not globally uniform.
FAQs
Is bedaquiline fumarate the same as Sirturo?
Bedaquiline fumarate is the active pharmaceutical ingredient and salt form used in Sirturo. Sirturo is the branded finished pharmaceutical product developed and marketed by Janssen.
Can generic bedaquiline be substituted for Sirturo?
Substitution depends on national approval, bioequivalence, procurement rules and the specific dosage form. An approved generic adult tablet may be substitutable under local law, while pediatric granules require separate regulatory consideration.
Does bedaquiline have orphan-drug exclusivity?
Bedaquiline received regulatory incentives associated with treatment of rare drug-resistant tuberculosis populations. Any orphan exclusivity period is separate from patent protection and does not extend indefinitely after the original approval.
Is bedaquiline included in the WHO Essential Medicines List?
Bedaquiline is included in international treatment guidance and is a key medicine for drug-resistant TB programs. Its precise listing and recommended use depend on the relevant edition and treatment category of the WHO guidelines.
What is the main investment risk for bedaquiline?
The main risk is erosion of branded price and share as generic suppliers qualify for public procurement. Volume growth from expanded MDR-TB treatment may offset part of that erosion, but the product’s financial profile is unlikely to resemble a long-term monopoly medicine.
References
- U.S. Food and Drug Administration. (2012). FDA approves new drug to treat multidrug-resistant tuberculosis. https://www.fda.gov
- World Health Organization. (2022). WHO consolidated guidelines on tuberculosis: Module 4, treatment: Drug-resistant tuberculosis treatment. World Health Organization.
- Medicines Patent Pool. (2023). Medicines Patent Pool and Johnson & Johnson announce licensing agreement for bedaquiline. https://medicinespatentpool.org
- Global Drug Facility. (2023). Bedaquiline access and procurement information. Stop TB Partnership. https://www.stoptb.org/global-drug-facility
- U.S. Food and Drug Administration. (2022). FDA approves new drug regimen for highly drug-resistant forms of tuberculosis. https://www.fda.gov
- Johnson & Johnson. (2023). Annual report. Johnson & Johnson. https://www.jnj.com
- U.S. Patent and Trademark Office. (2024). Patent Center and Patent Public Search. https://www.uspto.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov
